Acrobiosystems Inc.

Newark, DE

UEI
R1JEN78AMQD5
CAGE
875V5
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1 Innovation Way #302, Newark, DE 19711, USA
Founded
2010
Employees
251-1K
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $37,172
FY2025 $22,401
FY2024 $0
FY2023 $12,903

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Health and Human Services $37,172

Contract awards

Contract subawards

Prime contractor Prime award Amount Awarded
Gigagen Inc. NEXT GEN RECOMBINANT POLYCLONAL ANTIBODY DISCOVERY PLATFORM FOR THE DEVELPMENT OF MEDICAL COUNTERMEASURES Recombinant protein production 75A50124C00049 $227,628

Similar vendors

About the company

Acrobiosystems Inc., a for-profit biopharmaceutical manufacturer based in Newark, Delaware, supplies GMP-grade biologics and monoclonal antibodies to the National Institutes of Health Clinical Center as a prime contractor on firm fixed-price purchase orders, with one subcontract role under a medical countermeasures development program.

The vendor's federal footprint is concentrated within the Department of Health and Human Services. The NIH Clinical Center accounts for four awards and $72,000 in combined potential value across the portfolio; the National Institute of Allergy and Infectious Diseases holds one award valued at $11,000. A single subcontract sits with the Office of the Assistant Secretary for Preparedness and Response. Recent prime work includes a $21,835 purchase order (July 2026) for GMP-grade Human Interleukin-2 vials to support FDA-regulated cell and gene therapy manufacturing at the NIH Clinical Center's Center for Cellular Engineering; a $15,336.50 order (May 2026) for monoclonal anti-FMC63 antibody; a $22,401 order (March 2025) for GMP-grade Interleukin-2 reagent kits; and a $12,903 order (May 2023) for carrier-free monoclonal anti-FMC63 antibody. All four NIH Clinical Center awards were sole-source procurements justified by process-validation constraints — substituting alternative manufacturers would require regulatory revalidation with significant cost and schedule impact to clinical trial timelines. The vendor subcontracts to Gigagen Inc. on a recombinant polyclonal antibody discovery platform for medical countermeasures development (February 2025). Federal work sits within NAICS 325414 (Biological Product Manufacturing) and related diagnostics and life-sciences R&D codes, under PSC 6505 (Drugs and Biologicals) and diagnostic substance classifications.

Activity is sparse — one award in 2019, one in 2023, and two each in 2025 and 2026 — yielding six total awards since 2019 with $84,000 in combined potential value. One award completes within the next twenty-four months. The vendor does not hold any government-wide vehicles or BPAs; all awards are direct purchase orders from NIH Clinical Center.

Quick answers

Is Acrobiosystems Inc. registered in SAM.gov?

Yes. Acrobiosystems Inc.'s SAM.gov registration is active through April 23, 2027.

How much has Acrobiosystems Inc. received in federal contracts?

Federal contracts obligated $22,401 to Acrobiosystems Inc. in fiscal year 2025 and $72,476 in fiscal years 2023 through 2027.

What is Acrobiosystems Inc.'s most recent federal award?

Acrobiosystems Inc.'s most recent federal contract award is 26-006951 GMP grade human interleukin-2 (IL-2) (75N98026P01080), from Office of Logisitics and Acquisition Operations (NIH), on July 23, 2026.

On GovTribe

See Acrobiosystems Inc.'s full federal record

  • Federal contract awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors